Valeant (VRX) Audit Head Oversaw Similar Role At A FraudMani
Norma Provencio, who currently leads Valeant Pharmaceuticals board’s audit committee, was previously a director of a publicly traded company that failed after the government cracked down on a half-decade of fraud beginning in 2005.
Provencio was an accounting consultant before Signalife’s public offering, and starting in mid-2005, she was a director in charge of the board’s audit committee.
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.